<?xml version="1.0" encoding="UTF-8"?>
<p>Several studies with SARS‐CoV anti‐spike S‐protein antisera tested in cell lines or in laboratory animals indicate ADE (
 <xref rid="cytoa24047-bib-0031" ref-type="ref">31</xref>, 
 <xref rid="cytoa24047-bib-0032" ref-type="ref">32</xref>, 
 <xref rid="cytoa24047-bib-0033" ref-type="ref">33</xref>). Furthermore, the immune response and production of anti‐spike NAbs are accelerated in patients with fatal outcome (
 <xref rid="cytoa24047-bib-0042" ref-type="ref">42</xref>, 
 <xref rid="cytoa24047-bib-0043" ref-type="ref">43</xref>). In addition, enhancement of viral uptake dependent on RBD specific NAbs as well as on FcγRII is reported in vitro in MERS‐CoV (
 <xref rid="cytoa24047-bib-0024" ref-type="ref">24</xref>, 
 <xref rid="cytoa24047-bib-0030" ref-type="ref">30</xref>).
</p>
